Human medicines European public assessment report (EPAR): Nexviadyme, Avalglucosidase alfa, Glycogen Storage Disease Type II, Date of authorisation: 24/06/2022, Revision: 1, Status: Authorised
Nexviadyme is an enzyme replacement therapy used to treat patients with Pompe disease, a rare inherited disorder caused by the lack of an enzyme called alpha-glucosidase. Patients with Pompe disease have a build-up of glycogen (complex sugars) in body tissues, including the heart, lung and skeletal muscles, causing enlarged heart, breathing difficulties and muscle weakness.
Nexviadyme contains the active substance avalglucosidase alfa.
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
